פרוגרף 5 מג
astellas pharma international b.v., israel - tacrolimus - קפסולות - tacrolimus 5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients. treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.
פרוגרף 0.5 מג
astellas pharma international b.v., israel - tacrolimus - קפסולות - tacrolimus 0.5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients. treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.
פרוגרף 0.5 מג
astellas pharma international b.v., israel - tacrolimus - קפסולות - tacrolimus 0.5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients. treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.
רוויקטי 1.1 ג מל
medison pharma ltd - glycerol phenylbutyrate - נוזל - glycerol phenylbutyrate 1.1 g / 1 ml - glycerol phenylbutyrate
רוויקטי 1.1 ג מל
medison pharma ltd - glycerol phenylbutyrate - נוזל - glycerol phenylbutyrate 1.1 g / 1 ml - glycerol phenylbutyrate
רוויקטי 1.1 ג מל
medison pharma ltd - glycerol phenylbutyrate - נוזל - glycerol phenylbutyrate 1.1 g / 1 ml - glycerol phenylbutyrate
רוויקטי 1.1 ג מל
medison pharma ltd - glycerol phenylbutyrate - נוזל - glycerol phenylbutyrate 1.1 g / 1 ml - glycerol phenylbutyrate
רוויקטי 1.1 ג מל
medison pharma ltd - glycerol phenylbutyrate - נוזל - glycerol phenylbutyrate 1.1 g / 1 ml - glycerol phenylbutyrate
רוויקטי 1.1 ג מל
medison pharma ltd - glycerol phenylbutyrate - נוזל - glycerol phenylbutyrate 1.1 g / 1 ml - glycerol phenylbutyrate
נובוסבן אר.טי 1 מג בקבוקון
novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 1 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.